Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Endocrinology|January 15, 2021
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetesNiels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, et al.
Diabetes, Obesity & Metabolism|September 5, 2020
Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH<sub>2</sub> on GIP actions in humansLaerke Smidt Gasbjerg, Emilie J Bari, Signe Stensen, et al.
European Journal of Endocrinology|January 18, 2023
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humansLiva S L Krogh, Kristine Henriksen, Signe Stensen, et al.
Bone|July 31, 2020
The role of endogenous GIP and GLP-1 in postprandial bone homeostasisMads M Helsted, Lærke S Gasbjerg, Amalie R Lanng, et al.
JAMA Cardiology|December 23, 2025
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical TrialStephen J Nicholls, Donna H Ryan, John Deanfield, et al.
European Journal of Endocrinology|July 25, 2024
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trialLaura S Hansen, Lærke S Gasbjerg, Andreas Brønden, et al.
European Journal of Endocrinology|April 22, 2021
Effects of endogenous GIP in patients with type 2 diabetesSigne Stensen, Lærke S Gasbjerg, Liva L Krogh, et al.
The Journal of Clinical Endocrinology and Metabolism|February 21, 2020
GIP and GLP-1 Receptor Antagonism During a Meal in Healthy IndividualsLærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, et al.
Diabetes|January 11, 2019
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy IndividualsLærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
Pageof 2